

Intermonomer Electron Transfer between the Low-Potential *b* Hemes of Cytochrome *bc*₁[†]

Pascal Lanciano, Dong-Woo Lee,[‡] Honghui Yang,[§] Elisabeth Darrouzet,^{||} and Fevzi Daldal*

Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States. [‡]Present address: Industrial Biotechnology and Bioenergy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea 305-806. [§]Present address: State Key Laboratory of Multiphase Flow in Power Engineering, Xi'an Jiaotong University, Xi'an 710049, China. ^{||}Present address: CEA-iBEB, SBTN, Centre de Marcoule, Bat 170, BP17171, 30207 Bagnols sur Cèze, France.

Received October 28, 2010; Revised Manuscript Received January 19, 2011

ABSTRACT: Cytochrome (cyt) *bc*₁ is a structural dimer with its monomers consisting of the Fe-S protein, cyt *b*, and cyt *c*₁ subunits. Its three-dimensional architecture depicts it as a symmetrical homodimer, but the mobility of the head domain of the Fe-S protein indicates that the functional enzyme exists in asymmetrical heterodimeric conformations. Here, we report a new genetic system for studying intra- and intermonomer interactions within the cyt *bc*₁ using the facultative phototrophic bacterium *Rhodobacter capsulatus*. The system involves two different sets of independently expressed cyt *bc*₁ structural genes carried by two plasmids that are coharbored by a cell without its endogenous enzyme. Our results indicate that coexpressed cyt *bc*₁ subunits were matured, assorted, and assembled in vivo into homo- and heterodimeric enzymes that can bear different mutations in each monomer. Using the system, the occurrence of intermonomer electron transfer between the low-potential *b* hemes of cyt *bc*₁ was probed by choosing mutations that perturb electron transfer at the hydroquinone oxidation (Q_o) and quinone reduction (Q_i) sites of the enzyme. The data demonstrate that active heterodimeric variants, formed of monomers carrying mutations that abolish only one of the two (Q_o or Q_i) active sites of each monomer, are produced, and they support photosynthetic growth of *R. capsulatus*. Detailed analyses of the physicochemical properties of membranes of these mutants, as well as purified homo- and heterodimeric cyt *bc*₁ preparations, demonstrated that efficient and productive electron transfer occurs between the low-potential *b*_L hemes of the monomers in a heterodimeric enzyme. Overall findings are discussed with respect to intra- and intermonomer interactions that take place during the catalytic turnover of cyt *bc*₁.

The ubihydroquinone:cytochrome (cyt) *c* oxidoreductase (also called cyt *bc*₁¹ or complex III) is a major multisubunit membrane-bound enzyme that is central to respiratory and photosynthetic energy transduction pathways in various organisms (1). It converts hydroquinones (QH₂) to quinones (Q), reduces electron carrier cyt *c* forms, and contributes to the formation of membrane potential and proton gradient that are used for ATP production by ATP synthase (2, 3). In most bacteria, like the purple non-sulfur phototroph *Rhodobacter capsulatus*, cyt *bc*₁ consists of three subunits (the Fe-S protein, cyt *b*, and cyt *c*₁), which are encoded by three structural genes, *petA*, *petB*, and *petC*, respectively (4), located adjacent to each other to form the *petABC* operon (5). Cyt *b* is an integral membrane protein, whereas the Fe-S protein and cyt *c*₁ are membrane-anchored by their amino- and carboxyl-terminal helices, respectively. These subunits are universally conserved in all cyt *bc*₁ forms and always

carry specific cofactors essential for enzyme activity. These cofactors are the [2Fe-2S] cluster with a high redox midpoint potential (*E*_m) in the Fe-S protein, two *b*-type hemes with one low (*b*_L) and one high (*b*_H) *E*_m in cyt *b*, and a high-*E*_m *c*-type heme in cyt *c*₁ (6). The purified native *R. capsulatus* cyt *bc*₁ is a dimer but can also form tetramers upon fusion with one of its physiological electron carriers, the membrane-anchored cyt *c*_y (7). Each monomer of the enzyme contains two Q/QH₂ binding domains, termed the QH₂ oxidation (Q_o) and Q reduction (Q_i) sites, located on the positive (p) and negative (n) sides, respectively, of energy-transducing membranes. Three-dimensional structures for the cyt *bc*₁ forms of various organisms (including *R. capsulatus*) are known and often depict the enzyme as a symmetrical homodimer (8–11) (Figure 1). In each monomer (e.g., M1), the carboxyl-terminal helix of cyt *c*₁ interacts with the fifth helix of cyt *b* to form a cyt *bc*₁ core that interacts with only the head domain of the Fe-S protein, leaving the amino-terminal membrane helix of this subunit associated with cyt *b* of the other monomer (e.g., M2). The Fe-S protein head domain is mobile between cyt *b* and cyt *c*₁, and this mobility is essential for cyt *bc*₁ activity (12) as mutants with immobile Fe-S protein head domains are inactive (13). How the subunits are assembled to yield a functional enzyme is not well-established. Earlier works using *R. capsulatus* indicated that among the subunits and subcomplexes, the cyt *c*₁ subunit and the cyt *bc*₁ subcomplex are the longest-lived in vivo (14, 15). These observations suggested that

[†]This work was supported by grants from the National Institutes of Health (R01 GM 38237) and the U.S. Department of Energy (91ER 20052) to F.D.

*To whom correspondence should be addressed. Telephone: (215) 898-4394. Fax: (215) 898-8780. E-mail: fdaldal@sas.upenn.edu.

¹Abbreviations: cyt *bc*₁, ubihydroquinone:cytochrome *c* oxidoreductase; EPR, electron paramagnetic resonance; Fe-S, iron-sulfur; Q_o, hydroquinone oxidation; Q_i, quinone reduction; SQ, semiquinone; Ant, antimycin A; Myx, myxothiazol; Stig, stigmatellin; MPYE, mineral-peptide-yeast-extract; QH₂, hydroquinone; Q, quinone; MOPS, 4-morpholinepropanesulfonic acid; DBH₂, decylbenzohydroquinone; Flag, FLAG epitope; Strep, StrepTactin epitope.




FIGURE 1: Three-dimensional structure of dimeric *cyt bc₁* and its cofactors. The three-dimensional structure (Protein Data Bank entry 1ZRT for *R. capsulatus*) (left) of *cyt bc₁* depicts it as a dimeric enzyme with two identical monomers, M1 and M2, each consisting of the Fe-S protein (light blue), *cyt b* (dark blue in M1 and yellow in M2), and *cyt c₁* (beige). The figure was generated using Pymol (DeLano Scientific, San Carlos, CA), and the cofactors of each monomer ([2Fe-2S] cluster, hemes *b_L* and *b_H*, and *c₁*) are shown in different colors (blue in M1 and red in M2). Black and red arrows denote the electron transfer pathways between the cofactors and the *Q_o* and *Q_i* active sites of *cyt bc₁*, respectively. The intermonomer heme *b_L*–*b_L* distance is indicated with a dotted line, but for the sake of clarity, the distances (11) separating the cofactors are not shown. The right panel shows a schematic depiction of a homodimeric *cyt bc₁*, with its cofactors and *Q_o* and *Q_i* active sites, as described for the left panel.

first *cyt b* and *c₁* might assemble together to which the Fe-S protein is added, but how and when the monomers form a dimer remains unknown. Related subcomplexes, probably representing assembly intermediates of *cyt bc₁*, have also been observed with yeast mitochondria (16).

The mechanism of function of *cyt bc₁* is generally described by the Q cycle model (17) (see also ref 18). At the *Q_o* site, the oxidized [2Fe-2S] cluster of the Fe-S protein oxidizes QH₂ and conveys one of the two electrons emanating from QH₂ oxidation to oxidized *cyt c₁* via the mobility of the Fe-S protein head domain. *cyt c₁* then reduces another *cyt c* (in *R. capsulatus*, *cyt c_y* or *cyt c₂*), which transports electrons to the photochemical reaction center (RC) in photosynthesis (Ps) or the *cyt c* oxidase in respiration (Res). The second electron derived from QH₂ oxidation at the *Q_o* site is transferred to heme *b_L* of *cyt b* and is then conveyed to heme *b_H* across the lipid bilayer, to generate membrane potential and yield a stable semiquinone (SQ) at the *Q_i* site. Completion of the catalytic turnover of *cyt bc₁* involves a second QH₂ oxidation at a *Q_o* site, which proceeds via the same sequence of events described above but converting SQ in the *Q_i* site to a QH₂ to be released from the enzyme (Figure 1). Whether the same *Q_o* site of a given monomer, or the *Q_o* site at the other monomer of the dimeric enzyme, catalyzes this second QH₂ oxidation is unknown. In the past, models describing the mechanism of function of *cyt bc₁* using dimeric enzymes have been proposed (19, 20) (see also ref 21). Recent experimental data stemming from crystallography (22), enzyme kinetics (23, 24), and spectroscopy (25) suggest that intra- and intermonomer interactions occur in *cyt bc₁*, and that during the catalytic cycle the enzyme might become asymmetrical. The functional significance of any heterodimeric asymmetry remains unknown.

Our earlier works indicated that the presence of different *Q_i* site inhibitors affected the position of the Fe-S protein at the *Q_o* site across the membrane to initiate QH₂ oxidation (25). These intra- and intermonomer interactions led us to propose a “heterodimeric modified Q cycle” model (26). Accordingly, the resting enzyme would initiate a turnover at the *Q_o* site of any monomer

but then alternate between the *Q_o* sites of the two monomers to complete the initiated turnover. This model follows the Q cycle events (27, 28). In addition, it invokes intermonomer electron transfer between the *b_L* hemes of *cyt b* in each monomer to “dismutate” the two SQs accumulated at the distant *Q_i* sites of the dimeric enzyme to Q and QH₂ (26). More recent works indicated the occurrence of such electron transfer events (29, 30). To further probe our model, we sought approaches to studying homo- and heterodimeric interactions between the monomers of *cyt bc₁*. Here we describe a new genetic system that allows modifications at will of *cyt bc₁* subunits to induce structural asymmetry between monomers and yields architecturally heterodimeric enzymes. Successful production of heterodimeric *cyt bc₁* forms indicates that the enzyme subunits were matured, assorted, and assembled independently in *R. capsulatus* membranes. Using this system, we initiated dissection of intra- and intermonomer interactions within the dimeric *cyt bc₁* and describe a nativelike heterodimeric enzyme that exhibits fast and efficient electron transfer between the *b_L* hemes of the monomers to support *cyt bc₁*-dependent photosynthetic growth of *R. capsulatus*. Overall findings are discussed in terms of the biogenesis and mechanism of function of *cyt bc₁* in the context of the heterodimeric modified Q cycle model.

MATERIALS AND METHODS

Bacterial Strains and Growth Conditions. All *R. capsulatus* strains harboring plasmids that express *cyt bc₁* mutants were derivatives of strain MT-RBC1 [Δ (*petABC::spe*)] carrying a complete chromosomal deletion of *petABC* (5). They were grown in liquid or solid enriched (MPYE) medium, supplemented with antibiotics as needed (10 μ g/mL kanamycin, 2.5 μ g/mL tetracycline, or 10 μ g/mL spectinomycin) under Res (semiaerobic/dark) or Ps (photoheterotrophic/light) conditions at 35 °C as described in ref 4. For Ps growth, completely filled culture vessels or plates placed in anaerobic jars with H₂- and CO₂-generating gas packs (Becton Dickinson) were incubated in temperature-controlled Percival light incubators.

Escherichia coli strains harboring the plasmids used in this work (Table 1) were derivatives of HB101 [*F⁻ Δ*(*gpt-proA*)62 *araC14 leuB6*(Am) *glnV44*(AS) *galK2*(Oc) *lacY1 Δ*(*mcrC-mrr*) *rpsL20*(Str^r) *xylA5 mtl-1 thi-1*] and grown on Luria-Bertani medium containing ampicillin, kanamycin, or tetracycline (100, 50, or 12.5 μ g/mL, respectively) as appropriate (4). *R. capsulatus* strains harboring a single plasmid, or coharboring two plasmids with the same type of replicon or different (*incQ/P4* or *colE1*) types of replicons, were obtained via triparental matings between appropriate *E. coli* strains as donors and *R. capsulatus* strain MT-RBC1 as a recipient, as described previously (5). Depending on the replicon used, the desired plasmids were introduced by either conjugation or transformation, and either stepwise or simultaneously, using appropriate selections. Strains coharboring two plasmids were maintained using both antibiotics, and large cultures were subjected to short growth periods (~24 h). Under these conditions, cells harboring single or double plasmids produced Ps⁺ revertants at frequencies of <10⁻⁵, and cultures that occasionally yielded larger numbers of Ps⁺ revertants (>0.01%) were discarded so that biochemical analyses would not be compromised.

Molecular Genetic Techniques. Molecular genetic techniques were performed using standard procedures (31). All constructs were verified using DNA sequencing, and sequence

Table 1: Characteristics of the Different Plasmids Used in This Work

name	mutation	tag ^a	replicon ^b	resistance ^a	ref
pMTS1	no	no	incQ/P4	Kan ^R	38
pMTS1-S	no	S	incQ/P4	Kan ^R	this work
pMTS1-F	no	F	incQ/P4	Kan ^R	this work
pED2	<i>petB</i> :Y147A (Q _o site)	S	incQ/P4	Kan ^R	this work
pED3	<i>petB</i> :H212N (Q _i site)	F	fused incQ/P4+colE1	Tet ^R	this work
pHY101	<i>petB</i> :H212N (Q _i site)	F	incQ/P4	Tet ^R	this work
pHY103	<i>petB</i> :Y147A (Q _o site)	S	fused incQ/P4+colE1	Kan ^R	this work

^a*petB* is carboxyl-terminally epitope-tagged with S (StrepTactin) or F (FLAG) tags as indicated, and Kan^R and Tet^R refer to kanamycin and tetracycline resistance, respectively. ^bincQ/P4 and fused incQ/P4+colE1 refer to pRK-type and composite-type plasmids, respectively.

analyses were conducted using MacVector (Accelrys, San Diego, CA). Carboxyl-terminally epitope-tagged derivatives of cyt *b* were constructed using the “QuickChange Site-Directed Mutagenesis kit” (Stratagene, La Jolla, CA), with plasmid pPET1 carrying the wild-type *petABC* operon (5) as a template, and the primer pairs of FlagF1 (5′-TCCGGCCGAGGACTACAAG-GACGACGACGACAAGTGAGGAAAGGAACCG-3′) and FlagR1 (5′-CCTTTCCTCACTTGTCTGTCGTCGTCCTTGTA-GTCTCGGCCGGATTGCGG-3′) encoding the Flag (-DYK-DDDDK-COOH) (F) tag, StrepF1 (5′-TCCGGCCGAGTGGT-CGCACCCGACGTTGCGAAAAGTGAGGAAAGGAACCG-3′) and StrepR1 (5′-CCTTTCCTCACTTTCGAAGTGGGGT-GCGACCACTCGGCCGGATTGCGG-3′) encoding the Strep (-WSHPQFEK-COOH) (S) tag, HAF1 (5′-TCCGGCCGAG-TACCCGTACGACGTCCCGGACTACGCGTGAGGAAAG-GAACCG-3′) and HAR1 (5′-CCTTTCCTCACGCGTAGTCC-GGGACGTCGTACGGGTACTCGGCCGGATTGCGG-3′) encoding the HA (-YPYDVPDYA-COOH) (H) tag, or cMycF1 (5′-TCCGGCCGAGGAGCAGAAGCTTATCTCGGAGGAGG-ACCTGTGAGGAAAGGAACCG-3′) and cMycR1 (5′-CCTTTCCTCACAGGTCTCTCCGAGATAAGCTTCTGCTCCTC-GGCCGGATTGCGG-3′) encoding the cMyc (-EQKLISEEDL-COOH) (M) tag, yielding plasmids pPET1-F, pPET1-S, pPET1-H, and pPET1-M, respectively. The *XmaI*–*StuI* fragment of pMTS1 was then exchanged with its counterparts from appropriately tagged plasmid pPET1 derivatives to yield pMTS1-F, pMTS1-S, pMTS1-H, and pMTS1-M (Table 1). Similarly, pED2 (Kan^R) carrying a mutant allele of *petABC* with a cyt *b*-S:Y147A mutation that inactivates Q_o site electron transfer was obtained by exchanging the *XmaI*–*StuI* fragments between pPET1-S and pMTS1-*b*:Y147A plasmids (32). Plasmid pPET1-H212N* was obtained by exchanging the *StyI*–*SphI* fragments between pPET1-F and pPET1-H212N plasmids, and then the *BstEII* fragment carrying the cyt *b*-F:H212N mutation of pPET1-H212N* was substituted with that of pRKpPET1-bH212N (28) to yield pED3 (Tet^R). To construct plasmid pPHY101, which is a pRK415 Tet^R derivative carrying a mutant *petABC* with the cyt *b*-F:H212N mutation, pED3 was digested with *HindIII*, ligated, and transformed into HB101 selecting for Amp^R, to yield pPHY100 that carries *petABC*. This plasmid was digested with *TthIII*, blunt ended with T4 polymerase, and digested with *HindIII* to generate a DNA fragment carrying *petABC* with the cyt *b*-F:H212N mutation, which was ligated to Tet^R plasmid pRK415 digested first with *XbaI*, blunt ended with T4 polymerase, and then digested with *HindIII* to yield pPHY101 (Table 1). An Amp^R Tet^S derivative of plasmid pBR322 (33) was constructed by digestion with *EcoRV* and *AvaI*, religation, and transformation into HB101 to yield pPHY102. Ligation of plasmids pPHY102 and pED2 carrying *petABC* with the cyt *b*-S:Y147A mutation using their unique *HindIII* sites yielded plasmid

pPHY103. The characteristics of the plasmids used are summarized in Table 1.

Biochemical Techniques. Intracytoplasmic (chromatophore) membranes were obtained from frozen washed cells after two passes through a French pressure cell, as described previously (5). Protein concentrations were determined using the bicinchoninic acid method (34) with bovine serum albumin as a standard. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) (12.5%) was conducted as described in ref 35, and prior to being loaded, samples were solubilized by incubation for 10 min at room temperature in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 0.1 M dithiothreitol, 25% glycerol, and 0.01% bromophenol blue. Immunoblot analyses were conducted as described in ref 5 using polyclonal antibodies against *R. capsulatus* cyt *b*, or anti-Flag (Sigma Inc.) and anti-Strep antibodies (Novagen Inc.). Steady-state cyt *bc*₁ activity was measured using decylbenzohydroquinone (DBH₂) as an electron donor and horse heart cyt *c* as an electron acceptor at 25 °C (5). The reaction was initiated by enzyme addition and monitored at 550 nm for 2 min, and the portion of the initial rate that is sensitive to stigmatellin was taken as enzyme activity.

Spectroscopic Techniques. Optical spectra were recorded on a Hitachi U3210 UV–visible spectrophotometer. Absorption difference spectra for the *c*- and *b*-type cyts were obtained using chromatophore membranes (0.3 mg of total protein/mL), oxidized with potassium ferricyanide, and reduced with sodium ascorbate or sodium dithionite, as appropriate. Potentiometric dark titrations using optical or EPR spectra were performed with chromatophore membranes (1.5 or 10 mg/mL, respectively) or purified cyt *bc*₁ (0.5 mg/mL) preparations, as described previously (36). A buffer [50 mM MOPS and 100 mM KCl (pH 7.0)] containing 20 μM tetrachlorohydroquinone [TCHQ (*E*_{m,7} = 350 mV)], 20 μM 2,3,5,6-tetramethyl-1,4-phenylenediamine [DAD (260 mV)], 20 μM 1,2-naphthoquinone 4-sulfonate [NQS (210 mV)], 20 μM 1,2-naphthoquinone [NQ (145 mV)], 10 μM *N*-methylidibenzopyrazine methyl sulfate [PMS (80 mV)], 10 μM *N*-ethylidibenzopyrazine methyl sulfate [PES (50 mV)], 40 μM duroquinone [DQ (5 mV)], 20 μM pyocyanine [PCN (−34 mV)], 6 μM indigo trisulfonate [ITS (−90 mV)], 20 μM 2-hydroxy-1,4-naphthoquinone [HNQ (−145 mV)], and 20 μM anthraquinone 2-sulfonate [AQS (−225 mV)] as redox mediators was used. The optical changes that accompanied the *E*_h changes were recorded in the α-band region (500–600 nm), and the *E*_m values were determined by fitting the normalized absorption data to appropriate numbers of components *n* = 1 Nernst equation. The mediator cocktail was tested for the absence of any optical absorbance contribution during the titrations. EPR measurements were taken on a Bruker Elexsys E500 spectrometer. X-Band EPR spectra were recorded using a standard rectangular Bruker cavity (ER 4102ST)




FIGURE 2. Genetic system for studying intra- and intermonomer interactions in the cyt *bc*₁ dimer: cyt *b*-S:Y147A–cyt *b*-F:H212N heterodimeric cyt *bc*₁ variant in *R. capsulatus*. (A) The different plasmids carrying the *petABC* operon (left), their replicon type and antibiotic resistance markers (right), and the location of cyt *b* mutations in *petB* (middle) that they carry are shown together with the Strep (S) and Flag (F) epitope tags added at the carboxyl-terminal end of cyt *b*. The brackets are to indicate that pED2 and pPHY103 carry the same cyt *b* mutation but in two different replicons with the same antibiotic resistance marker, and the same is also the case for pED3 and pPHY101. (B) Coexpression of a Kan^R plasmid carrying the *petABC* operon with the cyt *b*-S:Y147A mutation and a Tet^R plasmid carrying the *petABC* operon with a cyt *b*-F:H212N mutation yields homodimeric cyt *b*-S:Y147A (left) and cyt *b*-F:H212N (right) as well as heterodimeric cyt *b*-S:Y147A–cyt *b*-F:H212N (middle) cyt *bc*₁ variants. The thin dotted arrows refer to residual electron transfer that occurs in the homodimeric cyt *b*-S:Y147A variant, whereas the thick red dashed arrows and thick blue solid arrows correspond to electron transfer to the high- and low-potential cofactors of cyt *bc*₁, respectively. Note that intermonomer heme *b*_L to *b*_L electron transfer is indicated by a thick blue solid arrow. (C) SDS–PAGE and immunoblot analyses of Strep- and Flag-tagged cyt *b* in chromatophore membranes of strains harboring different combinations of Kan^R and Tet^R plasmids (A–D, as indicated) producing heterodimeric cyt *bc*₁ variants. Approximately 10 μg of total proteins was used, and cyt *b* contents were determined using polyclonal antibodies specific to *R. capsulatus* cyt *b* (*b*) as well as commercially available antibodies against the Flag (F) and Strep (S) epitope tags. Properties of the plasmids used are described in Table 1.

fitted to an Oxford Instruments helium flow cryostat (ESR900). Spectrometer settings are listed in the figure legends.

Time-resolved, light-activated kinetic spectroscopy was performed on a dual-wavelength kinetic spectrophotometer with chromatophore membranes resuspended in 50 mM MOPS/100 mM KCl buffer (pH 7.0) supplemented with 100 μM ferricyanide [FeCN (430 mV)], 8 μM DAD (260 mV), 6 μM NQ (145 mV), 1 μM PMS (80 mV), 1 μM PES (50 mV), 6 μM 2 HNQ (−145 mV), and 6 μM benzyl viologen [BV (−359 mV)] as redox mediators and 2.5 μM valinomycin as a membrane potential uncoupler (37). The amounts of chromatophore membranes used in each assay were normalized to their reaction center (RC) content, as determined by measuring the flash-induced optical absorbance difference between 605 and 540 nm ($E_h = 380$ mV), and an extinction coefficient of 29.8 mM^{−1} cm^{−1}. Transient cyt *c* reduction and cyt *b* reduction kinetics at an E_h of 100 mV, initiated by a short saturating flash (~8 μs) from a xenon lamp, were followed at 550–540 and 560–570 nm, respectively. Antimycin, myxothiazol, and stigmatellin were used at 10 μM each, as needed.

Protein Purifications. *R. capsulatus* wild type, homo- or heterodimeric mutant, epitope-tagged, or untagged cyt *bc*₁ species were purified using appropriate derivatives of MT-RBC1 (Table 1). Washed chromatophore membranes were resuspended to a final protein concentration of 10 mg/mL in 50 mM Tris-HCl buffer (pH 8.0) containing 100 mM NaCl, 20% glycerol, and 1 mM PMSF. Dodecyl maltoside [DDM, 20% (w/v) stock solution] was added dropwise to a final concentration of 1 mg of detergent/mg of total protein. The mixture was stirred for 1 h at 4 °C and then ultracentrifuged (120000g for 1 h) to eliminate nondispersed membranes. The supernatant was loaded onto a DEAE-Biogel A column (5.2 cm × 15 cm) pre-equilibrated with 50 mM Tris-HCl (pH 8.0) containing 20% glycerol, 0.01% (w/v) DDM, and 100 mM NaCl (buffer A). The column was washed with 3 column volumes (CV) of buffer A, followed by 5 CV of the same buffer supplemented with 150 mM NaCl. With the cyt *bc*₁ variants derived from cells harboring pMTS1, pMTS1-S, pMTS1-F, and pED2, the column was washed stepwise between 150 and 350 mM NaCl until a red band adsorbed on top of the column became visible, which was then eluted with

350 mM NaCl. However, with the cyt *bc*₁ variant with the cyt *b*-F:H212N mutations produced by cells harboring pED3 or pED2+pED3, this red band started to elute at salt concentrations of >150 mM. In all cases, fractions were monitored for their absorption at 280 and 420 nm, and those with a reddish color, dithionite-reduced minus ferricyanide-oxidized optical difference spectra at 520–580 nm, were recorded. Fractions containing the highest concentrations of *c*- and *b*-type cyts were pooled, concentrated using an Amicon Diaflo apparatus equipped with a PM30 membrane, and stored at –80 °C. Concentrated cyt *bc*₁ preparations from cells carrying pMTS1-F or pED3 were passed twice through an anti-FLAG M2 affinity column (1 mL), pre-equilibrated with 15 CV of TBS [50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 20% glycerol, and 0.01% (w/v) DDM]. The column was washed with 10 CV of the same buffer and eluted with 6 CV of a solution containing 100 µg/mL FLAG peptide in TBS. Fractions containing cyt *bc*₁ were pooled, concentrated using Amicon Ultra (50000 *M_r* cutoff) centrifugal filter devices (Millipore Inc.), and stored at –80 °C in the presence of 20% glycerol until further use. In the case of cyt *bc*₁ variants derived from cells carrying pMTS1-S or pED2, concentrated samples were loaded twice onto a StrepTactin affinity column (1 mL) pre-equilibrated with 5 CV of TBS buffer. The column was washed with 10 CV of the same buffer and eluted with 6 × 0.5 CV of a solution containing 1 mM hydroxyazophenylbenzoic acid (HABA) in TBS. Fractions containing cyt *bc*₁ were pooled, concentrated using Amicon Ultra (50000 *M_r* cutoff) centrifugal filter devices (Millipore Inc.), and stored at –80 °C in the presence of 20% glycerol until further use. When affinity-purified cyt *bc*₁ samples were subjected to a second affinity chromatography using a different epitope (i.e., Flag to Strep or Strep to Flag), they were first concentrated and then processed as described above.

Chemicals. The cyt *bc*₁ inhibitors antimycin A, myxothiazol, and stigmatellin as well as duroquinone were purchased from Sigma Inc. Dodecyl maltoside was from Anatrace Inc., and DEAE-BioGel A was from Bio-Rad. All other chemicals were of reagent grade or of the highest quality commercially available.

RESULTS

A Genetic System for Studying Intra- and Intermonomer Interactions in cyt *bc*₁. A new genetic system that produces heterodimeric variants of cyt *bc*₁ was developed for studying intra- and intermonomer interactions in the *R. capsulatus* enzyme. In this system, alleles of *petA*, *petB*, and *petC* encoding cyt *bc*₁ subunits were carried by different plasmids marked with distinct antibiotic resistance markers (Kan^R and Tet^R) to ensure coselection (Figure 2A) and coexpressed in a strain devoid of its endogenous chromosomally encoded enzyme (5). We reasoned that coexpression of genetically distinct copies of cyt *bc*₁ structural genes might yield homodimeric and heterodimeric enzyme variants if the assembly and dimerization of different subunits occur randomly during cyt *bc*₁ biogenesis (Figure 2B). In addition, different epitope tags (Strep, Flag, HA, and cMyc) were added to the cyt *b* subunit of cyt *bc*₁ to physically distinguish the homo- and heterodimeric variants upon purification. Extension of the carboxyl-terminal end of a wild-type cyt *b* with any one of the four epitope-tags tested yielded functional cyt *bc*₁ variants that fully complemented for Ps growth a cyt *bc*₁[–] strain of *R. capsulatus*. The Strep- and Flag-tagged cyt *bc*₁ derivatives were

chosen for further experiments on the basis of their relative stabilities during subsequent purification procedures.

A Heterodimeric cyt *bc*₁ for Probing Intermonomer Electron Transfer between Its *b_L* Hemes. A heterodimeric cyt *bc*₁, with one inactive Q_i site in one monomer and one inactive Q_o site in the other monomer, was sought to investigate intermonomer electron transfer between the two *b_L* hemes of cyt *bc*₁ (Figure 2B). Earlier, we had reported that the cyt *b*:Y147A mutation abolishes the transfer of an electron from oxidized QH₂ to heme *b_L* without affecting the binding of Q or QH₂ to the Q_o site, the transfer of an electron from heme *b_L* to *b_H* (32), or the mobility of the Fe-S protein head domain between cyt *b* and cyt *c*₁ (12). Similarly, we had found that the cyt *b*:H212N mutation caused a loss of heme *b_H* without prohibiting enzyme assembly but enhanced the Fe-S protein head domain mobility at the Q_o site by decreasing intra- and intermonomer regulatory controls (25). These two mutations together with the Flag and Strep tags were used to produce “two-Q_o site defective homodimer” (cyt *b*-S:Y147A–cyt *b*-S:Y147A), “two-Q_i site defective homodimer” (cyt *b*-F:H212N–cyt *b*-F:H212N), and “one-Q_o site, one-Q_i site defective heterodimer” (cyt *b*-S:Y147A–cyt *b*-F:H212N) cyt *bc*₁ variants (Figure 2B). Moreover, earlier works indicated that the amounts of membrane proteins produced in *R. capsulatus* cells under different growth conditions depend on the plasmids used. A broad host-range plasmid of the pRK type (i.e., pMTS1) overproduced cyt *bc*₁, whereas a “composite” plasmid (i.e., pMTS0) obtained by fusing a pRK-type plasmid (i.e., pRK404) with a ColE1-type plasmid (i.e., pPET1) yielded variable levels of overproduction in different cases (5, 38). Thus, variants with cyt *b*-S:Y147A and cyt *b*-F:H212N substitutions carried by pRK-type (Kan^R pED2 and Tet^R pPHY101, respectively) or composite (Kan^R pPHY103 and Tet^R pED3, respectively) plasmids were constructed (Table 1), were conjugated into a cyt *bc*₁[–] mutant under Res growth conditions using appropriate Kan^R and Tet^R selections, and yielded cells harboring one or two different kinds of plasmids and producing homo- and heterodimeric cyt *bc*₁ variants.

Characterization of *R. capsulatus* Strains Producing Homo- and Heterodimeric cyt *bc*₁ Variants. *R. capsulatus* strains harboring a single plasmid with wild-type *petABC* (pMTS1, pMTS1-S, and pMTS1-F) were Ps⁺, and those with mutant *petABC* (pED2, pED3, pPHY101, and pPHY103) were Ps[–] (Figure 3A). Interestingly, cells harboring two plasmids in any of the four combinations tested (A, pED2 and pED3; B, pED2 and pPHY101; C, pPHY103 and pED3; and D, pPHY103 and pPHY101) exhibited slow Ps (i.e., Ps[±]) growth (Table 2), suggesting that concurrent expression of genetically distinct *petABC* operons yielded functional heterodimeric cyt *bc*₁ variants, which is a prerequisite for Ps growth of *R. capsulatus*. Indeed, use of SDS–PAGE and immunoblots with antibodies against cyt *b* as well as the Strep or Flag epitopes indicated that chromatophore membranes from the two plasmids harboring cells grown under Res conditions contained both Strep- or Flag-tagged cyt *bc*₁ variants (Figure 2C). Semiquantitative estimations suggested that among the four combinations, those containing two pRK-type (pED2 and pPHY101) or two composite (pPHY103 and pED3) plasmids produced comparable amounts of Strep- or Flag-tagged cyt *b* variants and revealed that this subunit was mature and assorted independently during cyt *bc*₁ biogenesis. Cells harboring pED2 and pED3 (combination A, cyt *b*-S:Y147A and cyt *b*-F:H212N) were retained for further studies. Under Ps growth conditions, cells harboring pED2 and pED3 formed




FIGURE 3: Photosynthetic growth phenotypes and biochemical properties of *R. capsulatus* strains producing heterodimeric cyt *bc*₁ variants. (A) Photosynthetic (Ps) growth on enriched medium of *R. capsulatus* strains harboring plasmids pMTS1, pMTS1-S, and pMTS1-F producing wild type, pED2+pED3 producing homodimeric cyt *b*-S:Y147A and cyt *b*-F:H212N, and pED2+pED3 producing heterodimeric cyt *b*-S:Y147A and cyt *b*-F:H212N cyt *bc*₁ variants. Cells harboring pMTS1, pMTS1-S, and pMTS1-F are Ps⁺; those harboring pED2 or pED3 are Ps⁻, and those harboring both pED2+pED3 are Ps[±] (i.e., slow growth). Shown above the plate a small section in which rare Ps⁺ revertants in pED2+pED3 cultures (indicated by arrows) are observed. (B) Chromatophore membranes of appropriate *R. capsulatus* strains described in panel A and grown by respiration in enriched medium were analyzed by SDS-PAGE (15%) and immunoblots using approximately 10 μ g of total proteins. The cyt *b* and cyt *c*₁ subunits were determined using polyclonal anti-cyt *b* or anti-cyt *c*₁ (right) or anti-Strep II and anti-Flag M2 (left) antibodies as indicated. (C) Total *b*-type and *c*-type cyt content of chromatophore membranes (0.3 mg/mL) obtained from appropriate *R. capsulatus* strains (as described for panel A) grown by respiration in enriched medium determined by ascorbate (---) or dithionite (—) reduced minus ferricyanide oxidized optical difference spectra. Note the differences seen between the strains harboring different plasmids and producing different cyt *bc*₁ variants. (D) Low-spin heme EPR spectra from redox-poised chromatophore membranes obtained from appropriate *R. capsulatus* strains (as described for panel A) grown by respiration in enriched medium. The ambient redox potential (*E*_h) values at which the spectra were recorded were 255, 260, 300, and 290 mV for membranes derived from cells harboring pMTS1, pED2, pED3, and pED2+pED3 plasmids, respectively. The following experimental conditions were used: temperature, 10 K; microwave power, 10 mW at 9.420 GHz; modulation amplitude, 10 G at 100 kHz; and four scans. Note that no baseline correction was used. (E) [2Fe-2S] EPR spectra of redox-poised chromatophore membranes obtained from appropriate *R. capsulatus* strains (as described for panel A) grown by respiration in enriched medium. The *E*_h values at which the spectra were recorded were 123, 112, 116, and 126 mV for membranes derived from cells harboring pMTS1, pED2, pED3, and pED2+pED3 plasmids, respectively. The following experimental conditions were used: temperature, 20 K; microwave power, 2 mW at 9.416 GHz; modulation amplitude, 20 G at 100 kHz; one scan.

smaller colonies than a wild-type strain, suggesting that they exhibited lower than normal levels of cyt *bc*₁ activity, while those

containing either pED2 or pED3 remained Ps⁻ (Figure 3A). Cells harboring either pED2 or pED3, or both pED2 and pED3,

Table 2: Characteristics of Various Homo- and Heterodimeric cyt *bc*₁ Variants

strain	Ps growth ^a	<i>b/c</i> ratio ^b	DBH ₂ activity ^c (%)	<i>E</i> _{m,7} ^d (mV)			dimer assembly ^e	
				<i>b</i> _L	<i>b</i> _H	<i>c</i> ₁	homo	hetero
pMTS1	+	1.6	100	−133	67	310	—	
pMTS1-S	+	1.6	106	nd ^g	nd ^g	nd ^g	SS	
pMTS1-F	+	1.7	80	nd ^g	nd ^g	nd ^g	FF	
pED2	—	1.7	13.2 ^f	−137	70	305	SS	
pHY103	—	nd ^g	nd ^g	nd ^g	nd ^g	nd ^g	SS	
pED3	—	0.5	9.2 ^f	−145	na ^h	300	FF	
pHY101	—	nd ^g	nd ^g	nd ^g	nd ^g	nd ^g	FF	
pED2+pED3 (A)	±	0.9	22	−147	73	300		FF+SS+FS
pED2+pHY101 (B)	±	1	19	nd ^g	nd ^g	nd ^g		FF+SS+FS
pED3+pHY103 (C)	±	0.75	17.5	nd ^g	nd ^g	nd ^g		FF+SS+FS
pHY101+pHY103 (D)	±	0.65	15	nd ^g	nd ^g	nd ^g		FF+SS+FS

^aPs refers to photosynthetic growth, and +, −, and ± denote vigorous, no, and slow growth ability, respectively. ^b*b/c* ratio refers to the cyt *b/cyt c* ratio determined by optical difference spectroscopy using membranes as described in Materials and Methods. ^cDBH₂ activity indicates the amount of DBH₂:cyt *c* reductase activity determined as described in Materials and Methods; 100% refers to the cyt *bc*₁ activity [1.74 μmol of cyt *c* reduced min^{−1} (mg of total membrane proteins)^{−1}] exhibited by cells harboring pMTS1. Note the variability of the values obtained which is consistent with the lability of heterodimeric enzymes. ^d*E*_{m,7} refers to the redox midpoint potentials of hemes *b*_L, *b*_H, and *c*₁ approximated as described in Materials and Methods. ^eSS, FF, and FS denote homo- and heterodimeric cyt *bc*₁ variants assembled, and A–D refer to Figure 2. ^fNote that 13.2% would correspond to 12.4% by taking as 100% the activity observed with cells harboring pMTS1-S. Similarly, 9.2% would correspond to 11.5% by taking as 100% the activity observed with cells harboring pMTS1-F. ^gNot done. ^hNot applicable.

yielded Ps⁺ revertants with similar frequencies of ~10^{−5} (data not shown). Inspections of cell populations harboring pED2 and pED3 indicated that more than 99.99% cells exhibited slow Ps[±] growth, which was distinct from the vigorous Ps⁺ growth of rare revertants (<0.01%) that occurred in the population (Figure 3A, top).

In agreement with the Ps phenotypes, chromatophore membranes of cells harboring pMTS1, pMTS1-S, and pMTS1-F plasmids had cyt *bc*₁ activities of ~1.74, ~1.85, and ~1.39 μmol of cyt *c* reduced min^{−1} (mg of total membrane proteins)^{−1}, respectively, whereas those with pED2 or pED3 yielded only 0.23 or 0.16 μmol of cyt *c* reduced min^{−1} (mg of total membrane proteins)^{−1}, respectively (~13 and 9% of the activity seen with wild-type pMTS1, respectively). Cells harboring two plasmids exhibited higher but somewhat variable (~22 to 15% of that of the wild type, partly because of enzyme lability) cyt *bc*₁ activities (Table 2), which could not be attributed to the rare revertants (at best forming 0.01% of the populations used). These data indicated that independent assortment of the two different variants of cyt *b* occurred in cells harboring two plasmids to yield functional heterodimeric cyt *bc*₁ variants in line with their slow Ps growth.

Additional analyses of chromatophore membranes by SDS–PAGE and immunoblots established that cells harboring pED2 and pED3 contained both cyt *b*-S and cyt *b*-F variants, and that the amounts of cyt *b* and cyt *c*₁ subunits detected using appropriate antibodies were similar to those observed with the corresponding wild-type strains (Figure 3B). Ascorbate or dithionite reduced minus ferricyanide oxidized optical difference spectra (Figure 3C) of chromatophore membranes were used to assess the amounts of total *c*-type and *b*-type cyts in different strains. As expected, the wild-type parent (pMTS1) and the cyt *b*-S:Y147A (pED2) mutant had more 560 nm-absorbing material than 550 nm-absorbing material attributed to the *b*- and *c*-type cyts, respectively. The cyt *b*-F:H212N (pED3) mutant showed the opposite pattern, in agreement with its missing heme *b*_H. Comparatively, membranes of cells harboring pED2 and pED3 had intermediate amounts of *b*- and *c*-type cyts, seemingly producing cyt *bc*₁ variants with different amounts of heme *b*_H (Figure 3C,D). Dark equilibrium redox titrations using

membranes derived from appropriate strains verified the thermodynamic properties of heme *b*_L, *b*_H, and *c*₁ cofactors of cyt *bc*₁ (Table 2). In these experiments, wild-type cyt *bc*₁ (pMTS1) displayed *E*_{m,7} values of −133, 67, and 310 mV for heme *b*_L, *b*_H, and *c*₁ cofactors, respectively. We note that these values appear to be slightly higher than those routinely observed, possibly because of the experimental conditions used here. The homodimeric cyt *bc*₁ mutant variants cyt *b*-S:Y147A and cyt *b*-F:H212N resulted in values of −137, 70, and 305 mV and values of −145, (62), and 300 mV for the heme *b*_L, *b*_H, and *c*₁ cofactors, respectively. Similar *E*_{m,7} values were obtained with membranes of cells harboring pED2 and pED3 (−147, 73, and 300 mV for heme *b*_L, *b*_H, and *c*₁ cofactors, respectively). We note that these *E*_{m,7} values should be considered approximate, especially in light of heterogeneous cyt *bc*₁ subpopulations in the membranes of these strains. The identity of cyt *b* species exhibiting an *E*_{m,7} value of (~60) mV in membranes of cells harboring pED3 (cyt *b*-F:H212N) is unknown, but it does not correspond to heme *b*_H, which is missing in this mutant (see EPR studies below and the Supporting Information). In any event, no major difference was seen among the *E*_{m,7} values of the heme *b*_H (when present), *b*_L, and *c*₁ cofactors of the homo- and heterodimeric cyt *bc*₁ variants (Table 2). However, note that these experiments could not determine whether the two *b*_L hemes of a heterodimeric cyt *bc*₁ variant have identical or different *E*_{m,7} values.

The cofactors associated with cyt *bc*₁ were also analyzed using EPR spectroscopy, especially to monitor hemes *b*_L and *b*_H, and the [2Fe-2S] cluster of cyt *bc*₁ in various mutants (Figure 3D,E). EPR resonance lines 3.78 and 3.43 corresponding to the *g*₂ features of oxidized hemes *b*_L and *b*_H, respectively, were detected in membranes derived from cells producing the wild type (pMTS1) and cyt *b*-S:Y147A variant (pED2) (39). Cells with the cyt *b*-F:H212N variant (pED3) lacked the *g*₂ feature at 3.43, while those harboring pED2 and pED3 had both of the *g*₂ features at 3.78 and 3.43. However, the amplitudes and shapes of the latter EPR spectra were distinct from those of a wild-type strain (Figure 3D). EPR dark equilibrium redox titrations of hemes *b*_L and *b*_H of cyt *bc*₁ were conducted to prevent any overlap with interfering component(s) with similar optical properties




FIGURE 4: Biochemical properties of partially purified *R. capsulatus* cyt *b*-S:Y147A–cyt *b*-F:H212N heterodimeric cyt *bc*₁ variants. (A) Homodimeric (FF and SS) and heterodimeric (FS) cyt *bc*₁ variants purified from cells harboring pED2 and pED3 by DEAE-Biogel A chromatography were analyzed by SDS–PAGE (12.5%) and immunoblots using approximately 5 μ g of proteins and anti-Strep II (α -Strep) or anti-Flag M2 (α -Flag) monoclonal antibodies. Fe-S protein, cyt *b*, and cyt *c*₁ subunits of cyt *bc*₁ are indicated. Note that Flag-tagged (pMTS1-F) and Strep-tagged (pMTS1-S) wild type and homodimeric cyt *b*-S:Y147A (pED2) and cyt *b*-F:H212N (pED3) cyt *bc*₁ variants were also purified but are not shown for the sake of clarity. (B) Total *b*-type and *c*-type cyt content of purified materials obtained from appropriate *R. capsulatus* strains (as described in the legend of Figure 2A) used to determine their ascorbate (---) or dithionite (—) reduced minus ferricyanide oxidized optical difference spectra. Note that these spectra are similar to those obtained using appropriate chromatophore membranes shown in Figure 3C. (C) Low-spin heme EPR spectra of purified materials obtained from appropriate *R. capsulatus* strains (as described in the legend of Figure 2A). All samples were oxidized directly in the EPR tube via addition of 5 μ L of 10 mM ferricyanide. The experimental conditions were as described in the legend of Figure 3D, and a “nonsignal” portion of a baseline spectrum simulated by a third-order polynomial fit was subtracted as a baseline correction.

(Figure S1A,B of the Supporting Information). These measurements indicated that hemes *b*_L and *b*_H that were detectable in membranes from cells harboring pED2 and pED3 producing heterodimeric cyt *bc*₁ variants had $E_{m,7}$ values comparable to those determined by optical titrations (Table 2 and Supporting Information). The EPR spectra of the Fe-S protein subunit of cyt *bc*₁ were also monitored. The Fe-S protein was present in similar amounts in all cases, as deduced from the g_y transition amplitudes of the reduced [2Fe-2S] clusters (Figure 3E). The shape and g_x (1.804) values of the Fe-S protein [2Fe-2S] cluster signals were identical in all mutants, indicating that the Q_o site Q/QH₂ occupancies of all cyt *bc*₁ variants were comparable. Overall, the data established that all strains, including those harboring pED2 and pED3, produced the expected cyt *bc*₁ mutant variants in similar amounts.

Purification and Characterization of Epitope-Tagged Homodimeric cyt *bc*₁ Variants. The properties of cells harboring pED2 and pED3 enticed us to seek direct physical evidence of the occurrence of active heterodimeric cyt *bc*₁ species under appropriate conditions. A two-step purification method, starting with anion exchange chromatography with a DEAE-Biogel A column (15) followed by epitope tag affinity chromatography, yielded large quantities of purified, epitope-tagged wild-type (pMTS1-S and pMTS1-F) and single-mutant (pED2 and pED3) cyt *bc*₁ homodimers for biochemical characterizations (Table 2, Figure 4A, data and not shown). Purified wild-type Strep-tagged (pMTS1-S) and Flag-tagged (pMTS1-F) cyt *bc*₁ had activities of 8.3 and 7.7 μ mol of cyt *c* reduced min^{-1} (mg of total proteins)^{−1}, respectively. In contrast, purified mutant cyt *b*-S:Y147A (pED2) and cyt *b*-F:H212N (pED3) variants had ~10-fold lower activities of 0.8 and 0.5 μ mol of cyt *c* reduced min^{-1} (mg of total proteins)^{−1}, respectively. SDS–PAGE and immunoblots with cyt *b* and epitope tag antibodies, as well as optical and EPR

spectral analyses (Figure 4B,C), indicated that the properties of purified, epitope-tagged homodimeric cyt *bc*₁ variants were comparable to those of their membrane-embedded versions. Only the cyt *b*-F:H212N (pED3) variant lacking heme *b*_H was unstable and aggregated rapidly. This mutant enzyme did not bind tightly to the DEAE-Biogel A column at salt concentrations of >150 mM NaCl, rendering its purification difficult, in contrast to the other variants that remained bound at salt concentrations of up to 350 mM.

Physical Evidence of the Production of a Heterodimeric cyt *bc*₁ in *R. capsulatus*. Despite the difficulties encountered with the cyt *b*-F:H212N mutant, we purified epitope-tagged heterodimeric cyt *bc*₁ variants from cells harboring pED2 and pED3 by DEAE-Biogel A chromatography followed by two consecutive affinity chromatography steps. DEAE-Biogel A chromatography yielded partially purified and active epitope-tagged cyt *bc*₁ [~ 2 μ mol of cyt *c* min^{-1} (mg of total proteins)^{−1}] with expected optical and EPR spectra (Figure 4). These preparations were expected to contain both homodimeric (called SS and FF for cyt *b*-S:Y147A and cyt *b*-F:H212N, respectively) and heterodimeric (called FS for cyt *b*-S:Y147A–cyt *b*-F:H212N) cyt *bc*₁ populations. They were further fractionated into homodimeric (FF and SS) and heterodimeric (FS) cyt *bc*₁ variants by two consecutive affinity chromatography steps (Flag followed by Strep binding columns, and Strep followed by Flag binding columns) (Figure S2A,B of the Supporting Information). In both cases, final elution fractions contained highly enriched heterodimeric cyt *b*-S:Y147A–cyt *b*-F:H212N (FS) variants of cyt *bc*₁, which had no enzymatic activity. Nonetheless, the successful isolation of FS subpopulations by two consecutive affinity chromatography steps in either order confirmed the occurrence of heterodimeric cyt *bc*₁ species in cells harboring pED2 and pED3 plasmids (Supporting Information).




FIGURE 5: Light-induced, time-resolved *cyt b* reduction and *cyt c* re-reduction kinetics of various *R. capsulatus* strains. *R. capsulatus* strains harboring plasmids pMTS1 producing wild-type, pED2 and pED3 producing homodimeric *cyt b*-S:Y147A and *cyt b*-F:H212N, respectively, and pED2+pED3 producing heterodimeric *cyt b*-S:Y147A–*cyt b*-F:H212N *cyt bc*₁ variants were analyzed. In each case, chromatophore membranes corresponding to an amount of RC equal to 0.30 μ M were resuspended in 50 mM MOPS buffer (pH 7.0) containing 100 mM KCl at an E_h of 100 mV. The exact amount of RC was determined from the extent of its photo-oxidation after a train of 10 flashes, separated by 50 ms at an E_h of 380 mV (top panel) and an extinction coefficient of 29 $\text{mM}^{-1} \text{cm}^{-1}$ at 605 nm minus 540 nm, as described in Materials and Methods. In all samples, *cyt c* re-reduction kinetics (middle panel) were monitored at 550 nm minus 540 nm, in the absence of inhibitor (no), or in the presence of 10 μ M myxothiazol (Myx), which abolishes QH_2 oxidation at the Q_o site, or 10 μ M stigmatellin (Stig), which abolishes the transfer of an electron from the [2Fe-2S] cluster to heme c_1 by immobilizing the head domain of the Fe-S protein subunit at the Q_o site. Similarly, *cyt b* reduction kinetics (bottom panel) were monitored at 560 nm minus 570 nm, in the absence of inhibitor (no), or in the presence of 10 μ M Q_i site inhibitor antimycin (Ant). Note that the samples of pED2 were analyzed using slightly different equipment, which yielded a signal-to-noise ratio higher than those of the other samples.

Light-Activated, Single-Turnover *cyt c* and *cyt b* Reduction Kinetics of Homo- and Heterodimeric *R. capsulatus cyt bc*₁. The slow Ps growth ability of cells harboring pED2 and pED3 plasmids indicated that they conducted photosynthetic cyclic electron transport upon light activation. The *cyt c* and *cyt b* reduction kinetics were monitored using chromatophore membranes derived from cells harboring homo- or heterodimeric *cyt bc*₁ variants using light-activated, time-resolved optical kinetic spectroscopy (Figure 5). Chromatophore membranes of various strains were normalized per amount of photochemical reaction center (RC) that they contained (Figure 5, top panel). Millisecond time scale *cyt c* (Figure 5, middle panel) and *cyt b* (Figure 5, bottom panel) reduction kinetics were monitored at an ambient potential (E_h) of 100 mV with the wild type (pMTS1) as well as the homodimeric and heterodimeric *cyt bc*₁ variants (pED2, pED3, and pED2+pED3). As expected, chromatophore membranes of the wild-type strain exhibited submillisecond time scale oxidation, followed by *cyt c* re-reduction kinetics in the millisecond range (40). Addition of myxothiazol or stigmatellin inhibited the *cyt c* re-reduction kinetics partly or completely,

respectively (Figure 5, left column, middle row). Stigmatellin revealed the full extent of *cyt c* oxidation by inhibiting Q_o site catalysis and immobilizing the Fe-S protein head domain at this site, while myxothiazol inhibited only QH_2 oxidation, leaving the Fe-S protein head domain mobile (8). Fast *cyt c* re-reduction kinetics were not seen in membranes derived from cells carrying either pED2 or pED3, even in the absence of inhibitor, in agreement with their lacking an active *cyt bc*₁ (Figure 5, two middle columns, middle rows). Membranes of cells harboring the *cyt b*-S:Y147A (pED2) variant exhibited reduction kinetics slightly faster than those seen with *cyt b*-F:H212N (pED3), and these kinetics were fully inhibited upon addition of inhibitors, as reported previously (32). The extents of *cyt c* oxidation seen with inactive *cyt bc*₁ mutants in the absence of inhibitor were almost similar to those observed with wild-type *cyt bc*₁ in the presence of inhibitors. Thus, these mutants did not contain active *cyt bc*₁ species, in agreement with their Ps[−] phenotype. Interestingly, membranes of cells harboring pED2 and pED3 exhibited *cyt c* re-reduction kinetics that were faster than those carrying pED2 or pED3 but slower than those seen with membranes from wild-type




FIGURE 6: Light-induced, time-resolved cyt *b* reduction kinetics exhibited by *R. capsulatus* strains harboring different plasmid combinations yielding heterodimeric cyt *bc*₁ variants. The cyt *b* reduction kinetics were monitored using chromatophore membranes prepared from appropriate cells (pMTS1, pED2+pED3, pED2+pHY101, pED3+pHY103 and pHY101+pHY103) grown in enriched medium under respiratory growth conditions. All plasmid combinations (A–D) are described in the legend of Figure 2 and Table 1. Experimental conditions were as described in the legend of Figure 5, using chromatophore membranes containing 0.30 μ M RC, appropriate mediators (Materials and Methods), 3 μ M valinomycin, and 10 μ M antimycin A. Samples were poised at 100 mV. Note that the extent and rate of cyt *b* reduction change depending on the strains, with cells harboring identical replicons exhibiting more pronounced kinetics, possibly reflecting better electronic couplings in membranes harboring heterogeneous cyt *bc*₁ subpopulations.

cyt *bc*₁-producing cells (Figure 5, right column, middle row). In all cases, the cyt *c* re-reduction kinetics were sensitive to myxothiazol and stigmatellin (38), indicating that they reflected cyt *bc*₁ specific activities. Kinetic patterns similar to cyt *c* re-reduction kinetics were also observed with cyt *b* reduction kinetics (Figure 5, bottom panel). Upon addition of antimycin A, which eliminates the transfer of an electron from cyt *b*_H to Q at the Q_i site, rapid cyt *b* reduction was seen with membranes derived from cells producing wild-type cyt *bc*₁, but not with those that have a defective enzyme lacking heme *b*_H (pED3), or an extremely slow Q_o site catalysis (pED2). In the presence of antimycin A, membranes from cells harboring pED2 and pED3 exhibited readily detectable cyt *b* reduction kinetics, although these kinetics were slower and had amplitudes smaller than those seen with membranes from cells producing wild-type cyt *bc*₁ (Figure 5, right vs left columns, bottom row). In all cases, the cyt *b* reduction kinetics were sensitive to the Q_o site inhibitors myxothiazol and stigmatellin, confirming that they originated from Q_o site catalysis. The cyt *c* re-reduction and cyt *b* reduction kinetics seen with membranes of cells harboring the cyt *b*-S:Y147A–cyt *b*-F:H212N variants of cyt *bc*₁ (pED2+pED3) established that the heterodimeric enzymes were active and able to sustain cyclic electron transport between the RC and cyt *bc*₁ to support Ps growth. As the homodimeric enzymes are inactive, we concluded that heterodimeric cyt *bc*₁ variants effectively conduct electron transfer between the *b*_L hemes of their two monomers (Figure 2B, middle panel).

The Extent of cyt *b* Reduction Depends on the Amount of Heterodimeric cyt *bc*₁ Present in Cells. As different plasmids with different replication properties yielded different amounts of heterodimeric cyt *bc*₁ based on SDS–PAGE and immunoblot data, we examined membranes derived from cells harboring the four different combinations (A, B, C, and D) of plasmids (Figure 2C) producing heterodimeric cyt *bc*₁ variants. The extents of cyt *b* reduction were monitored in the presence of antimycin A using membrane preparations normalized per amount of RC (Figure 6). The data indicated that membranes from cells harboring identical plasmids (i.e., pRK-type pED2+pHY101, or composite pED3+pHY103) exhibited more pronounced cyt *b* reduction and cyt *c* re-reduction kinetics. Under identical light activation conditions, the detection of larger extents of cyt *b* kinetics per amount of RC suggested that larger amounts of heterodimeric cyt *bc*₁ were electronically coupled to the RCs. These experiments documented that the new genetic system used here has the ability to produce different amounts of heterodimeric cyt *bc*₁ variants, changing the coupling ratios between the

physiological Ps electron transport partners in chromatophore membranes.

DISCUSSION

Static three-dimensional structural models often depict cyt *bc*₁ as a dimer of two identical monomers (8–11, 22) (Figure 1). However, the mobility of the Fe-S protein subunit during hydroquinone oxidation at the Q_o site indicates that the enzyme undergoes large conformational changes during its catalytic turnover (41). These considerations led us to the “heterodimeric modified Q cycle” model (26), which was reviewed recently by Cooley (42). In our work, we developed a new genetic system for examining intra- and intermonomer interactions in cyt *bc*₁ and used it to test the occurrence of intermonomer electron transfer between the *b*_L hemes of this enzyme. We thought that if a heterodimeric cyt *bc*₁ with only one active Q_o site in one monomer and one active Q_i site in the other monomer is obtained by coexpression of two *petABC* operons, then intermonomer electron transfer between the *b*_L hemes could be probed. However, neither the degree of recombination *in vivo* that might occur between homologous copies of *petABC* carried by two plasmids nor which specific mutation(s) to use to inactivate the Q_o and Q_i sites was known (6). We found that the Ps⁺ reversion rates observed in cells harboring two similar plasmids, comaintained using two antibiotic resistance markers, were not exorbitantly high as compared with those carrying only one plasmid. To avoid the mutations that affect the occupancy of the Q binding sites or those that immobilize the Fe-S protein head domain, we opted for the cyt *b*:Y147A and cyt *b*:H212N mutations that we had characterized previously (12, 32). To the best of our knowledge, the heterodimeric cyt *bc*₁ obtained in this work (Figure 7) is the first example of such an enzyme that is sufficiently active to sustain Ps growth. This cyt *bc*₁ variant remains active, conserves its subunit stoichiometry upon detergent solubilization and DEAE-Biogel A chromatography, but loses its activity during subsequent affinity purification. Matrix-induced inactivation observed with wild-type *R. capsulatus* cyt *bc*₁ (15) might account for the loss of activity. However, as Strep-tagged wild-type and cyt *b*-S:Y147A enzymes were readily purified without loss of activity using the same columns, the observed instability and the poor DEAE-Biogel A binding properties of the heterodimeric cyt *b*-S:Y147A–cyt *b*-F:H212N variant are probably due to the intrinsic instability of cyt *bc*₁ in the absence of its heme *b*_H. The four-helix bundle that coordinates hemes *b*_L and *b*_H defines the interface between the two monomers and is a key feature for the

molecules that accumulated at the Q_i sites to Q and QH_2 to initiate the next turnover of cyt bc_1 (26). Recently, Cooley has discussed structural elements of cyt b that might govern Q_o – Q_i site interactions across the membrane, such as the formation of SQ at one of the Q_i sites allowing the cognate Q_o site ef loop to act as a temporal “gate” for the initiation of the next QH_2 oxidation (42). If such a gate exists, then how long this gate remains “closed” might depend on how stable the SQ is at the Q_i site. Q_i site mutants with increased SQ K_{stab} at the Q_i site, like the cyt b : H217R substitutions, produce functional but less active homodimeric cyt bc_1 variants (38), suggesting that extreme stability of SQ may be required to inactivate cyt bc_1 completely. In agreement with this suggestion, a fused cyt b –cyt b hybrid containing cyt bc_1 -like enzyme formed from one fully active and one both Q_o and Q_i site inactive monomers apparently remains active (29). Undoubtedly, the ongoing use of different genetic systems that produce heterodimeric cyt bc_1 variants would be invaluable in assessing the validity of current catalytic models invoking dimeric cyt bc_1 .

ACKNOWLEDGMENT

We thank N. Selamoglu for critical reading of the manuscript and acknowledge the Johnson Research Foundation for use of EPR and kinetic spectroscopy facilities, without which this work would have been impossible. We also thank Drs. P. L. Dutton and C. Moser for their help.

SUPPORTING INFORMATION AVAILABLE

EPR dark equilibrium redox titrations of hemes b_L and b_H of heterodimeric cyt bc_1 variants using chromatophore membranes (Figure S1A,B) and physical evidence of the production of heterodimeric cyt bc_1 variants using DEAE-Biogel A chromatography followed by two consecutive affinity chromatography steps (Figure S2A,B). This material is available free of charge via the Internet at <http://pubs.acs.org>.

REFERENCES

- Berry, E. A., Guergova-Kuras, M., Huang, L. S., and Crofts, A. R. (2000) Structure and function of cytochrome bc complexes. *Annu. Rev. Biochem.* 69, 1005–1075.
- Mitchell, P. (1976) Possible molecular mechanisms of the protonmotive function of cytochrome systems. *J. Theor. Biol.* 62, 327–367.
- Trumpower, B. L. (1990) The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc_1 complex. *J. Biol. Chem.* 265, 11409–11412.
- Daldal, F., Davidson, E., and Cheng, S. (1987) Isolation of the structural genes for the Rieske Fe-S protein, cytochrome b and cytochrome c_1 all components of the ubiquinol:cytochrome c_2 oxidoreductase complex of *Rhodospseudomonas capsulata*. *J. Mol. Biol.* 195, 1–12.
- Atta-Asafo-Adjei, E., and Daldal, F. (1991) Size of the amino acid side chain at position 158 of cytochrome b is critical for an active cytochrome bc_1 complex and for photosynthetic growth of *Rhodobacter capsulatus*. *Proc. Natl. Acad. Sci. U.S.A.* 88, 492–496.
- Berry, E. A., Lee, D.-W., Huang, L.-S., and Daldal, F. (2009) Structural and Mutational Studies of the cytochrome bc_1 complex. In *The Purple Phototrophic Bacteria* (Hunter, C. N., Daldal, F., Thurnauer, M. C., and Beatty, J. C., Eds.) pp 425–450, Springer, Berlin.
- Lee, D. W., Ozturk, Y., Osyczka, A., Cooley, J. W., and Daldal, F. (2008) Cytochrome bc_1 - c_2 fusion complexes reveal the distance constraints for functional electron transfer between photosynthesis components. *J. Biol. Chem.* 283, 13973–13982.
- Zhang, Z., Huang, L., Shulmeister, V. M., Chi, Y. I., Kim, K. K., Hung, L. W., Crofts, A. R., Berry, E. A., and Kim, S. H. (1998) Electron transfer by domain movement in cytochrome bc_1 . *Nature* 392, 677–684.
- Xia, D., Yu, C. A., Kim, H., Xia, J. Z., Kachurin, A. M., Zhang, L., Yu, L., and Deisenhofer, J. (1997) Crystal structure of the cytochrome bc_1 complex from bovine heart mitochondria. *Science* 277, 60–66.
- Iwata, S., Lee, J. W., Okada, K., Lee, J. K., Iwata, M., Rasmussen, B., Link, T. A., Ramaswamy, S., and Jap, B. K. (1998) Complete structure of the 11-subunit bovine mitochondrial cytochrome bc_1 complex. *Science* 281, 64–71.
- Berry, E. A., Huang, L. S., Saechao, L. K., Pon, N. G., Valkova-Valchanova, M., and Daldal, F. (2004) X-ray Structure of *Rhodobacter capsulatus* Cytochrome bc_1 : Comparison with its Mitochondrial and Chloroplast Counterparts. *Photosynth. Res.* 81, 251–275.
- Darrouzet, E., Valkova-Valchanova, M., Moser, C. C., Dutton, P. L., and Daldal, F. (2000) Uncovering the $[2Fe2S]$ domain movement in cytochrome bc_1 and its implications for energy conversion. *Proc. Natl. Acad. Sci. U.S.A.* 97, 4567–4572.
- Darrouzet, E., Valkova-Valchanova, M., and Daldal, F. (2000) Probing the role of the Fe-S subunit hinge region during Q_o site catalysis in *Rhodobacter capsulatus* bc_1 complex. *Biochemistry* 39, 15475–15483.
- Davidson, E., Ohnishi, T., Tokito, M., and Daldal, F. (1992) *Rhodobacter capsulatus* mutants lacking the Rieske FeS protein form a stable cytochrome bc_1 subcomplex with an intact quinone reduction site. *Biochemistry* 31, 3351–3358.
- Valkova-Valchanova, M. B., Saribas, A. S., Gibney, B. R., Dutton, P. L., and Daldal, F. (1998) Isolation and characterization of a two-subunit cytochrome b - c_1 subcomplex from *Rhodobacter capsulatus* and reconstitution of its ubihydroquinone oxidation (Q_u) site with purified Fe-S protein subunit. *Biochemistry* 37, 16242–16251.
- Zara, V., Conte, L., and Trumpower, B. L. (2007) Identification and characterization of cytochrome bc_1 subcomplexes in mitochondria from yeast with single and double deletions of genes encoding cytochrome bc_1 subunits. *FEBS J.* 274, 4526–4539.
- Crofts, A. R., Meinhardt, S. W., Jones, K. R., and Snozzi, M. (1983) The role of the quinone pool in the cyclic electron transfer chain of *Rhodospseudomonas sphaeroides*: A Modified Q-cycle mechanism. *Biochim. Biophys. Acta* 723, 202–218.
- Osyczka, A., Moser, C. C., and Dutton, P. L. (2005) Fixing the Q cycle. *Trends Biochem. Sci.* 30, 176–182.
- Gopta, O. A., Feniouk, B. A., Junge, W., and Mulkidjanian, A. Y. (1998) The cytochrome bc_1 complex of *Rhodobacter capsulatus*: Ubiquinol oxidation in a dimeric Q-cycle? *FEBS Lett.* 431, 291–296.
- Trumpower, B. L. (2002) A concerted, alternating sites mechanism of ubiquinol oxidation by the dimeric cytochrome bc_1 complex. *Biochim. Biophys. Acta* 1555, 166–173.
- Crofts, A. R., Holland, J. T., Victoria, D., Kolling, D. R., Dikanov, S. A., Gilbreth, R., Lhee, S., Kuras, R., and Kuras, M. G. (2008) The Q-cycle reviewed: How well does a monomeric mechanism of the bc_1 complex account for the function of a dimeric complex? *Biochim. Biophys. Acta* 1777, 1001–1019.
- Solmaz, S. R., and Hunte, C. (2008) Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer. *J. Biol. Chem.* 283, 17542–17549.
- Covian, R., and Trumpower, B. L. (2005) Rapid electron transfer between monomers when the cytochrome bc_1 complex dimer is reduced through center N. *J. Biol. Chem.* 280, 22732–22740.
- Gong, X., Yu, L., Xia, D., and Yu, C. A. (2005) Evidence for electron equilibrium between the two hemes b_L in the dimeric cytochrome bc_1 complex. *J. Biol. Chem.* 280, 9251–9257.
- Cooley, J. W., Ohnishi, T., and Daldal, F. (2005) Binding dynamics at the quinone reduction Q_i site influence the equilibrium interactions of the iron sulfur protein and hydroquinone oxidation Q_o site of the cytochrome bc_1 complex. *Biochemistry* 44, 10520–10532.
- Cooley, J. W., Lee, D. W., and Daldal, F. (2009) Across membrane communication between the Q_o and Q_i active sites of cytochrome bc_1 . *Biochemistry* 48, 1888–1899.
- Crofts, A. R., Barquera, B., Gennis, R. B., Kuras, R., Guergova-Kuras, M., and Berry, E. A. (1999) Mechanism of ubiquinol oxidation by the bc_1 complex: Different domains of the quinol binding pocket and their role in the mechanism and binding of inhibitors. *Biochemistry* 38, 15807–15826.
- Osyczka, A., Moser, C. C., Daldal, F., and Dutton, P. L. (2004) Reversible redox energy coupling in electron transfer chains. *Nature* 427, 607–612.
- Swierczek, M., Cieluch, E., Sarewicz, M., Borek, A., Moser, C. C., Dutton, P. L., and Osyczka, A. (2010) An electronic bus bar lies in the core of cytochrome bc_1 . *Science* 329, 451–454.
- Castellani, M., Covian, R., Kleinschroth, T., Anderka, O., Ludwig, B., and Trumpower, B. L. (2010) Direct demonstration of half-of-the-sites reactivity in the dimeric cytochrome bc_1 complex: Enzyme with one inactive monomer is fully active but unable to activate the second ubiquinol oxidation site in response to ligand binding at the ubiquinone reduction site. *J. Biol. Chem.* 285, 502–510.

31. Sambrook, J., and Russel, D. W. (2001) Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Plainview, NY.
32. Saribas, A. S., Ding, H., Dutton, P. L., and Daldal, F. (1995) Tyrosine 147 of cytochrome *b* is required for efficient electron transfer at the ubihydroquinone oxidase site (Q_o) of the cytochrome *bc*₁ complex. *Biochemistry* 34, 16004–16012.
33. Bolivar, F., Rodriguez, R. L., Greene, P. J., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, J. H., and Falkow, S. (1977) Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. *Gene* 2, 95–113.
34. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. *Anal. Biochem.* 150, 76–85.
35. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680–685.
36. Dutton, P. L. (1978) Redox potentiometry: Determination of mid-point potentials of oxidation-reduction components of biological electron-transfer systems. *Methods Enzymol.* 54, 411–435.
37. Saribas, A. S., Valkova-Valchanova, M., Tokito, M. K., Zhang, Z., Berry, E. A., and Daldal, F. (1998) Interactions between the cytochrome *b*, cytochrome *c*₁, and Fe-S protein subunits at the ubihydroquinone oxidation site of the *bc*₁ complex of *Rhodobacter capsulatus*. *Biochemistry* 37, 8105–8114.
38. Gray, K. A., Dutton, P. L., and Daldal, F. (1994) Requirement of histidine 217 for ubiquinone reductase activity (Q_i site) in the cytochrome *bc*₁ complex. *Biochemistry* 33, 723–733.
39. Salerno, J. C. (1984) Cytochrome electron spin resonance line shapes, ligand fields, and components stoichiometry in ubiquinol-cytochrome *c* oxidoreductase. *J. Biol. Chem.* 259, 2331–2336.
40. Robertson, D. E., Davidson, E., Prince, R. C., van den Berg, W. H., Marrs, B. L., and Dutton, P. L. (1986) Discrete catalytic sites for quinone in the ubiquinol-cytochrome *c*₂ oxidoreductase of *Rhodopseudomonas capsulata*. Evidence from a mutant defective in ubiquinol oxidation. *J. Biol. Chem.* 261, 584–591.
41. Darrouzet, E., Moser, C. C., Dutton, P. L., and Daldal, F. (2001) Large scale domain movement in cytochrome *bc*₁: A new device for electron transfer in proteins. *Trends Biochem. Sci.* 26, 445–451.
42. Cooley, J. W. (2010) A structural model for across membrane coupling between the Q_o and Q_i active sites of cytochrome *bc*₁. *Biochim. Biophys. Acta* 1797, 1842–1848.
43. Davidson, E., Ohnishi, T., Atta-Asafo-Adjei, E., and Daldal, F. (1992) Potential ligands to the [2Fe-2S] Rieske cluster of the cytochrome *bc*₁ complex of *Rhodobacter capsulatus* probed by site-directed mutagenesis. *Biochemistry* 31, 3342–3351.